Roche Collaborates with Icagen for the Development of Drug Candidates for Neurological Disorders
Shots:
- Icagen to receive upfront- up to $274M milestones and royalties on sales from Roche and is responsible for all preclinical activities
- Roche to fund the program and will perform further development and commercialization activities
- The focus of the collaboration is to develop pre-clinical stage ion channel modulators using Icagen's drug discovery platform- for targeting ion channel in neurons
Ref: Icagen | Image: Roche
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com